Xenon Outlines Key Corporate Milestone Opportunities for 2025
Topline data from the first Phase 3 FOS study anticipated in H2 2025 representing major milestone in support of NDA filing and potential launch ...
Morningstar16d
Xenon to Present at the 43rd Annual J.P. Morgan Healthcare Conference
VANCOUVER, British Columbia and BOSTON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering ...
manilatimes16d
Xenon to Present at the 43rd Annual J.P. Morgan Healthcare Conference
VANCOUVER, British Columbia and BOSTON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, ...
Nasdaq10d
Xenon Pharmaceuticals Outlines Clinical Milestones and Pipeline Progress for 2025, Including Phase 3 Studies for Azetukalner
Xenon Pharmaceuticals provided an update on its pipeline programs, highlighting significant progress and upcoming milestones for 2025. The company anticipates topline data from its first Phase 3 ...
Nasdaq10d
Xenon Outlines Key Corporate Milestone Opportunities for 2025
VANCOUVER, British Columbia and BOSTON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering ...
Finanznachrichten10d
Xenon Pharmaceuticals Inc.: Xenon Outlines Key Corporate Milestone Opportunities for 2025
- Topline data from the first Phase 3 FOS study anticipated in H2 2025 representing major milestone in support of NDA filing and potential launch of azetukalner - First of three planned Phase 3 MDD ...
Stockhouse10d
Xenon Outlines Key Corporate Milestone Opportunities for 2025
VANCOUVER, British Columbia and BOSTON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, ...